Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 380,700 | 1,069,400 | 978,200 | 687,900 | 356,400 |
| Depreciation Amortization | 40,900 | 156,600 | 113,900 | 74,700 | 36,600 |
| Income taxes - deferred | 9,400 | -117,600 | -63,200 | -45,200 | -24,300 |
| Accounts receivable | -117,900 | -23,000 | -55,400 | -68,600 | -43,700 |
| Other Working Capital | -501,500 | 154,600 | -99,700 | -292,400 | -150,700 |
| Other Operating Activity | 232,200 | 355,200 | 270,500 | 214,200 | 106,100 |
| Operating Cash Flow | $43,800 | $1,595,200 | $1,144,300 | $570,600 | $280,400 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -64,900 | -260,200 | -162,800 | -105,300 | -56,000 |
| Net Acquisitions | -35,100 | -25,100 | -19,600 | -17,000 | -3,000 |
| Purchase Of Investment | -659,900 | -3,199,900 | -2,358,200 | -1,325,900 | -647,300 |
| Sale Of Investment | 722,600 | 2,841,800 | 2,163,600 | 1,471,700 | 845,600 |
| Other Investing Activity | -55,500 | -69,500 | -137,600 | -110,300 | -54,000 |
| Investing Cash Flow | $-92,800 | $-712,900 | $-514,600 | $-86,800 | $85,300 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 68,900 | 174,100 | 141,800 | 107,100 | 49,900 |
| Common Stock Repurchased | -421,800 | -893,400 | -852,800 | -264,100 | -258,600 |
| Other Financing Activity | -98,300 | -237,500 | -234,400 | -48,300 | -49,300 |
| Financing Cash Flow | $-451,200 | $-956,800 | $-945,400 | $-205,300 | $-258,000 |
| Exchange Rate Effect | 8,200 | -44,800 | -48,300 | -47,300 | -17,700 |
| Beginning Cash Position | 2,939,500 | 3,058,800 | 3,058,800 | 3,058,800 | 3,058,800 |
| End Cash Position | 2,447,500 | 2,939,500 | 2,694,800 | 3,290,000 | 3,148,800 |
| Net Cash Flow | $-492,000 | $-119,300 | $-364,000 | $231,200 | $90,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 43,800 | 1,595,200 | 1,144,300 | 570,600 | 280,400 |
| Capital Expenditure | -64,900 | -260,200 | -162,800 | -105,300 | -56,000 |
| Free Cash Flow | -21,100 | 1,335,000 | 981,500 | 465,300 | 224,400 |